Author:
Blanco F F,Jimbo M,Wulfkuhle J,Gallagher I,Deng J,Enyenihi L,Meisner-Kober N,Londin E,Rigoutsos I,Sawicki J A,Risbud M V,Witkiewicz A K,McCue P A,Jiang W,Rui H,Yeo C J,Petricoin E,Winter J M,Brody J R
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference71 articles.
1. ACS Cancer Facts & Figures 2013. American Cancer Society: Atlanta, GA, USA, 2014. Available at http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913–2921.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801–1806.
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献